Navigating Biotech in a Shifting Landscape

This chapter explores the current economic challenges impacting biotech investments, highlighting a decline in startup formations despite increased funding. The conversation focuses on the implications of recent drug development failures, anticipated mergers and acquisitions, and the strategic shift towards licensing deals within the pharmaceutical industry. As the JPMorgan Healthcare Conference approaches, insights into company strategies and the overall mood of the sector provide a portrait of the evolving biotech landscape.